Hepta Bio

Hepta Bio

Private
CaliforniaHealthcare & Life Scienceshttps://hepta.bio

Last Round

Seed

Nov 5, 2025

Total Funding Raised

$6.7M

Momentum Score

50 /100

Company Overview

Hepta Bio is a biotechnology company that develops a liquid biopsy and AI platform to read the cell-free DNA epigenome and detect organ-specific signals of chronic disease, with an initial focus on metabolic dysfunction-associated steatohepatitis (MASH).

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical AI, Precision Medicine, Healthcare Analytics, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service, Government Contracts

AI Layer

Application

Keywords

liquid biopsynon-invasive diagnosticsMASHepigenomicscell-free DNAcfDNAAI diagnosticsliver biopsy alternativechronic disease detectionliver disease detectionprecision medicinemolecular diagnosticsMetabolic Dysfunction-Associated Steatohepatitisclinical trial diagnostics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Hepta Bio Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Hepta Bio Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
SeedNov 5, 2025

Key People

Founding team and executive leadership

Soheil Damangir

Co-Founder And CTO

Founding Team

Hamed Amini

Co-founder CEO

Founding Team

Hepta Bio Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 19, 2026

    Monthly visitors increased 35% MoM, reaching 2.8K.

  • Nov 5, 2025

    $7M round completed.

Hepta Bio Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Hepta Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Hepta Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersCalifornia
Employee Range6
Year Founded2022
Last FundingNov 5, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.